Remicade (Infliximab) in Pregnancy: FDA Category B – Risks & Considerations

FDA Pregnancy Category B (no human risk in controlled studies; animal studies show no fetal harm).

Clinical Guidance

  • Use only if clearly needed; benefit > risk.
  • Consider discontinuation if disease controlled without it.
  • If continued, time infusions to minimize placental transfer in 3rd trimester (IgG crosses increasingly after 30 weeks).
  • Live vaccines (rotavirus, BCG) deferred in infant until 6–12 months if exposed in utero.

Breastfeeding

Infliximab present in milk at low levels; generally considered compatible, but discuss with provider.

Shared decision-making with rheumatologist and OB is essential.

Pregnancy & Health - Related Articles